Polypharmacology of clinical sodium glucose co‐transport protein 2 inhibitors and relationship to suspected adverse drug reactions

Abstract Sodium glucose co‐transporter 2 inhibitors (SGLT2i) are a promising second‐line treatment strategy for type 2 diabetes mellitus (T2DM) with a developing landscape of both beneficial cardio‐ and nephroprotective properties and emerging adverse drug reactions (ADRs) including diabetic ketoaci...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Karan Matharu, Kiran Chana, Charles J. Ferro, Alan M. Jones
Format: article
Langue:EN
Publié: Wiley 2021
Sujets:
Accès en ligne:https://doaj.org/article/2165848a28d741d482d78c9b86e58971
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!